Your Global Leader in Stem Cell Market Research
Traditionally known for tech products, Amazon, Google, and Apple are beginning covert ventures into yet another critical sphere of human life, healthcare.
With hundreds of thousands of health-related apps available globally, more than 320 million users engaging with these platforms, and over 600 million wearable devices projected to ship annually by 2026, it is no surprise that companies like Google, Apple, and Amazon are investing heavily in cutting-edge healthcare technologies. [Read more…]
Palo Alto, CA – I Peace, Inc., a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalized iPS cell production and longevity-focused rejuvenation therapies in the United States.
I Peace CEO Koji Tanabe spoke at the “Unlimited Health Conference,” a part of the Vitalist Bay, the biggest longevity event in the world, which is held in Berkeley, California. The event was held on April 5. [Read more…]
Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine. Cord blood stem cells have distinct advantages over other sources, including that they are:
• Younger
• More adaptable
• More pure
These traits result from cord blood stem cells being the earliest (non-controversial) stem cells that can be extracted from a living human, and therefore haven’t been exposed to viruses, chemicals, or pollutants in the environment that can alter cell function.
While bone marrow stem cells are the most commonly recognized type of stem cell used in transplant, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant. Although cord blood banks began offering their services in the United States in the mid-1990’s, it is within the past ten-years that the percentage of cord blood transplants has significantly increased.
Today, it is clear that the stem cells contained within cord blood banking have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide. However, many expectant parents still do not fully understand the significance of cord blood storage.
Unfortunately, a study published in the 2006 Journal of Reproductive Medicine showed that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” The study also identified that 84% of prenatal patients expected their obstetricians to be able to provide them with information on the subject of cord blood banking; however, only about 14% were educated about cord blood banking by their nurse or obstetrician.
Subsequently, a 2014 Parent Survey conducted by BioInformant Worldwide, LLC (600+ responses from recent and expectant parents), identified that these percentages have shifted very little since 2006, despite attempts in most countries worldwide to encourage healthcare providers to offer prenatal patients balanced information on public and private cord blood banking options.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.
Stem cells are unique for the role they play. They are effectively the body’s raw material – the cells from which all other cells with specialized functions are created, such as those which constitute our blood, brain, or bone.
According to Sleepedia, that is not the only way they are unique. One of the defining features of stem cells is that unlike other cells, they don’t exhaust themselves. After undertaking their duties, they are able to enter a state of hibernation which allows for self-renewal.
They effectively go to sleep and in doing so they make themselves young again, a process known as reversible quiescence. In the body these sleeping stem cells can then remain dormant for years until called into action again. [Read more…]
Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
